Sartorius Stedim Biotech S.A. saw a 14% drop in its stock price following a quarterly earnings report that, while meeting revenue expectations at €762 million, missed statutory earnings forecasts by 7.2%, recording €0.91 per share. Analysts have adjusted their earnings models, now predicting revenues of €3.17 billion and a 44% increase in earnings per share to €3.97 by 2026, though this reflects a slight downgrade from previous estimates. Overall, sentiment has declined despite no significant changes to revenue forecasts or the consensus price target of €232, indicating a stable valuation amidst a forecasted growth rate in line with industry averages. Investors are advised to consider the longer-term trajectory and potential risks associated with the company.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/fr/pharmaceuticals-biotech/epa-dim/sartorius-stedim-biotech-shares/news/earnings-miss-sartorius-stedim-biotech-sa-missed-eps-by-72-a
